You generally should not start testosterone therapy if you have cirrhosis without a hepatologist and endocrinologist approving it first, and many people with cirrhosis should avoid it. The liver clears testosterone and converts it to other hormones, and scarring changes that balance. Testosterone can also raise red blood cell counts and fluid retention, which are risky in portal hypertension. Testosterone is not a proven treatment for low testosterone caused by liver disease itself. Decisions must weigh the cause of cirrhosis, the severity score, and the reason for treatment.
How the liver handles testosterone
The liver sits at the center of androgen metabolism, and cirrhosis disrupts each step. Testosterone binds to sex hormone-binding globulin (SHBG) and albumin in the blood, and the liver makes both proteins. When cirrhosis lowers albumin and shifts SHBG, the free fraction of testosterone changes. The liver also converts testosterone to estradiol through the enzyme aromatase, so scarred liver tissue can alter estrogen-to-androgen ratios. In men, this shift helps explain gynecomastia, spider angiomas, and testicular shrinkage. Put simply, the liver is both a clearinghouse and a converter for sex hormones, and cirrhosis jams both functions.
The liver also clears testosterone by first-pass metabolism after oral doses. Oral testosterone undecanoate passes through the portal vein straight into the liver, which is why oral androgens carry a boxed warning for liver injury. Transdermal gels and injections bypass that first pass, but they still raise circulating levels that the damaged liver must process. A failing liver clears hormones more slowly, so the same dose can produce higher and longer-lasting blood levels. The mechanism is slower clearance plus altered protein binding, not a single broken switch.
Cirrhosis also changes the hypothalamic-pituitary-gonadal axis. Chronic liver disease lowers testosterone production at the testicle and raises estrogen conversion in fat and muscle. The pituitary may send weaker signals, and the result is a mixed picture called hypogonadism of chronic liver disease. That low testosterone is often secondary to the liver disease and systemic illness, not the primary problem. Treating the number with exogenous testosterone may not fix the underlying cause and can add new risks.
Quantified context: how common and how severe
Low testosterone is common in men with cirrhosis. Studies of men with advanced liver disease report low total or free testosterone in roughly 50 to 90 percent of cases, depending on the threshold and the severity of disease. The prevalence rises with Child-Pugh class, so people with decompensated cirrhosis are most affected. Free testosterone can look low even when total testosterone is normal because SHBG rises. This is why a single total testosterone level can mislead in liver disease.
Liver injury from androgens is dose- and duration-dependent. Historic reports of oral androgen liver toxicity described jaundice, peliosis hepatis (blood-filled cavities in the liver), and liver tumors, often after months to years of high-dose oral therapy. Modern transdermal and injectable products avoid the first-pass route and carry lower hepatic risk, but the FDA still requires liver-related warnings on androgen products. The exact risk with modern formulations is not well quantified in cirrhosis, and that uncertainty matters.
The severity score guides the decision. A Child-Pugh score of A means compensated disease, while B and C mean more advanced cirrhosis with worse synthetic function. A MELD score above roughly 10 to 15 signals meaningful decompensation risk. Someone with Child-Pugh A and normal platelets may tolerate therapy with monitoring better than someone with ascites and varices. There is no validated threshold that makes testosterone safe, so severity is a weighing factor, not a green light.
Edge cases that change the answer
The cause of cirrhosis matters. Alcohol-related cirrhosis can improve with abstinence, and testosterone may rise on its own after months of sobriety, so treating early can be premature. Metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis often coexists with obesity and low testosterone, and weight loss can raise testosterone without drugs. Hemochromatosis damages the pituitary and testicles directly, so the hormone problem may be primary and need endocrine workup. Autoimmune hepatitis and primary biliary cholangitis have their own steroid and immune considerations.
The reason for testosterone matters just as much. If the goal is treating symptomatic hypogonadism confirmed on two morning blood tests, the case is stronger than if the goal is body composition or fatigue alone. Fatigue in cirrhosis has many causes, including anemia, sleep disturbance, and hepatic encephalopathy, and testosterone rarely fixes those. If the goal is preserving muscle mass, resistance training and nutrition often outperform hormones in this population. A clear, documented indication is the first filter.
Portal hypertension is the hidden edge case. Testosterone raises hematocrit by stimulating erythropoietin, and a hematocrit above roughly 54 percent thickens the blood and raises thrombosis risk. Fluid retention from androgen aromatization to estradiol can worsen ascites and edema. In someone with esophageal varices, a bleeding risk already exists, and adding volume overload or clotting changes is a real concern. These are the reasons hepatologists approach androgen therapy in cirrhosis with caution rather than enthusiasm.
Here is a counterintuitive caveat from clinical practice. Some men with cirrhosis and low testosterone feel better on therapy, but the improvement can come from better sleep, mood, and anemia correction rather than from the hormone itself. The placebo and lifestyle effects are real, and a trial without objective endpoints can mislead. Measurable goals, like hematocrit, lean mass, and symptom scores, keep the decision honest.
Misconceptions worth correcting
One misconception is that testosterone is a liver tonic. Androgens do not reverse fibrosis, and no major liver society recommends testosterone for cirrhosis itself. The hormone may help symptoms of hypogonadism, but it does not treat the scar tissue. Expecting liver improvement from testosterone sets up disappointment and unnecessary risk.
Another misconception is that natural or "bioidentical" testosterone is safer for the liver. The liver does not distinguish synthetic from natural hormones, and the route of administration matters more than the label. Oral products carry the clearest liver warnings regardless of branding. Compounded creams and pellets have variable absorption, which makes monitoring harder in a population that needs precision.
A third misconception is that a normal total testosterone rules out hypogonadism. In cirrhosis, SHBG often rises, so total testosterone can look normal while free testosterone is low. Measuring free or bioavailable testosterone, or calculating a free androgen index, gives a better picture. Morning samples are important because testosterone peaks between roughly 7 and 10 a.m. Two abnormal morning results, not one, should drive a diagnosis.
A fourth misconception is that testosterone always worsens liver tests. Modern transdermal and injectable products usually cause only small enzyme changes, and many people tolerate them. The real risks are erythrocytosis, fluid retention, and prostate effects, not routine liver enzyme spikes. Still, new jaundice, dark urine, or right-upper-quadrant pain on therapy needs urgent evaluation.
New or worsening jaundice, dark urine, or pale stools Rapid weight gain, swelling, or worsening ascites New abdominal pain or tender liver enlargement Shortness of breath, chest pain, or leg swelling Confusion or drowsiness suggesting encephalopathy A rising hematocrit above roughly 52 to 54 percent
Comparison table: testosterone options in liver disease
| Option | Route | Liver first-pass? | Monitoring needs | Practical notes |
|---|---|---|---|---|
| Testosterone gel | Transdermal | No | Hematocrit, PSA, symptoms | Daily use, transfer risk to others |
| Testosterone injection (cypionate/enanthate) | Intramuscular | No | Hematocrit, PSA, trough levels | Peaks and troughs; 1-4 week intervals |
| Testosterone undecanoate injection | Intramuscular | No | Hematocrit, PSA, levels | Long-acting, clinic-administered |
| Oral testosterone undecanoate | Oral | Yes | Liver enzymes, hematocrit, lipids | Boxed liver warning; avoid in cirrhosis |
| Compounded cream or pellet | Variable | Usually no | Levels, hematocrit, PSA | Absorption varies; harder to monitor |
| No therapy, lifestyle first | Not applicable | Not applicable | Weight, sleep, strength | Safer first step in many cases |
Timeline table: what to expect when therapy is considered
| Time point | What happens | What to check |
|---|---|---|
| Before starting | Confirm diagnosis and severity | Two morning testosterone levels, Child-Pugh or MELD, complete blood count, PSA |
| Week 2-4 | Early hormone response | Symptom review, blood pressure, fluid status |
| Week 6-12 | Hematocrit begins to rise | Complete blood count; hold if hematocrit climbs toward 54 percent |
| Month 3 | First formal reassessment | Testosterone level, hematocrit, liver enzymes, prostate symptoms |
| Month 6 | Steady-state check | Repeat labs; reassess goals and benefits |
| Month 12 | Annual review | Liver imaging if indicated, bone density if risk factors present |
| Any time | Red flags | Jaundice, ascites, confusion, chest pain trigger urgent care |
The timeline matters because androgen effects accumulate. Hematocrit can rise for months before symptoms appear, and fluid retention can tip someone with marginal reserve into overt ascites. Early checks catch these changes before they become emergencies. The schedule should be tighter in decompensated disease and looser in compensated disease, but never absent.
Practical actions and thresholds
Start with diagnosis, not prescription. Confirm low testosterone with two morning total testosterone measurements, and add free testosterone or SHBG when liver disease is present. Morning values below roughly 300 ng/dL total are commonly used as a low threshold, but reference ranges vary by lab. Free testosterone below the lab's lower limit supports the diagnosis when total is borderline. Document symptoms like low libido, fatigue, and lost muscle mass before treating.
Stage the liver disease. Ask for a Child-Pugh score, a MELD score, and a platelet count. Platelets below roughly 100,000 per microliter suggest portal hypertension and warrant varice screening if not already done. An ultrasound or elastography result helps confirm cirrhosis and its severity. These numbers shape the risk conversation more than any single hormone level.
If therapy is chosen, prefer non-oral routes. Transdermal gels and injectable esters avoid first-pass liver exposure and are easier to monitor than oral products. Check hematocrit at baseline, then at 6 to 12 weeks, then at 3 and 6 months, and then every 6 to 12 months. Hold or reduce therapy if hematocrit approaches 54 percent. Check prostate-specific antigen at baseline and per age-appropriate guidelines.
Address reversible causes first. Abstaining from alcohol for 3 to 6 months can raise testosterone in alcohol-related disease. Weight loss of 5 to 10 percent of body weight can raise testosterone in obesity-related disease. Treating sleep apnea and correcting iron overload in hemochromatosis also help. These steps cost little and carry no hormonal risk.
Set objective goals and a stop rule. Define success as improved libido, strength, or anemia within 3 to 6 months. If those goals are not met, stop rather than escalate. Track hematocrit, fluid weight, and liver enzymes at each visit. A written stop rule prevents open-ended therapy in a high-risk population. Prices vary widely, so treat cost as a secondary factor behind safety.
Limitations and what remains unknown
The evidence base for testosterone in cirrhosis is thin. Most studies are small, observational, or focused on men without advanced liver disease. No large randomized trial has established safety in Child-Pugh B or C cirrhosis. That means recommendations rest on mechanism and expert caution, not on strong outcome data. Honest counseling should say so plainly.
Monitoring standards are also not liver-specific. Hematocrit thresholds come from general testosterone guidance, not cirrhosis trials. Prostate monitoring assumes life expectancy and screening preferences that may differ in advanced liver disease. Fluid retention risk is real but poorly quantified in this group. Clinicians must extrapolate, and patients should know that extrapolation is happening.
Finally, liver transplantation changes the picture. Testosterone often improves after transplant as liver function recovers, so starting therapy before transplant may be premature. After transplant, immunosuppressants and comorbidities alter risk again. The answer to whether you can take testosterone with cirrhosis is therefore conditional, not fixed. It depends on cause, severity, indication, and monitoring, and it should be answered by a team, not a label.